Skip to main content

Valneva Value Stock - Dividend - Research Selection

Valneva SE

ISIN: FR0004056851, WKN: A0MVJZ

Market price date: 20.01.2022
Market price: 16,54 EUR

Valneva SE Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 30-06-2021
Cash flow
Net operating cash flow 137.738.000
Capital Expenditures -18.936.000
Free cash flow 118.802.000
Balance sheet
Total Equity 77.422.000
Liabilities & Shareholders equity 449.164.000
Income statement
Net income -64.393.000
Eps (diluted) -0,709
Diluted shares outstanding 90.824.200
Net sales/revenue 110.322.000

Fundamental ratios calculated on: 20-01-2022

Key figures 20-01-2022
Cash flow
P/C 10,91
P/FC 12,65
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization1.821.991.808,00 USD
Raw Data SourceIFRS in Millionen EUR
Stock Split2015-01-15,1201.000000/1083.000000; 2013-06-17,1874.000000/1675.000000; 2010-07-05,713.000000/632.000000

Description of the company

Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,